Neos Therapeutics Inc. (NASDAQ:NEOS)’s share price was up 4% on Monday . The company traded as high as $8.89 and last traded at $8.89, with a volume of 87,665 shares. The stock had previously closed at $8.55.

A number of equities analysts have weighed in on NEOS shares. BMO Capital Markets started coverage on Neos Therapeutics in a report on Tuesday, June 28th. They issued an “outperform” rating and a $15.00 price target for the company. Zacks Investment Research cut Neos Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, May 18th. Royal Bank Of Canada decreased their price target on Neos Therapeutics from $33.00 to $29.00 and set an “outperform” rating for the company in a report on Tuesday, May 17th. Finally, Wells Fargo & Co. restated a “buy” rating on shares of Neos Therapeutics in a report on Wednesday, May 18th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. Neos Therapeutics currently has a consensus rating of “Buy” and an average price target of $21.75.

The firm has a 50-day moving average price of $9.65 and a 200-day moving average price of $9.95. The company’s market capitalization is $142.00 million.

Neos Therapeutics (NASDAQ:NEOS) last announced its quarterly earnings data on Monday, May 16th. The company reported ($0.79) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.87) by $0.08. On average, equities analysts forecast that Neos Therapeutics Inc. will post ($4.88) earnings per share for the current year.

In other Neos Therapeutics news, Director Gregory J. Robitaille acquired 7,442 shares of the firm’s stock in a transaction on Wednesday, May 18th. The stock was purchased at an average cost of $7.55 per share, for a total transaction of $56,187.10. Following the transaction, the director now owns 55,677 shares of the company’s stock, valued at approximately $420,361.35. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, major shareholder Presidio Partners 2007, L.P. sold 20,367 shares of the firm’s stock in a transaction dated Wednesday, April 20th. The stock was sold at an average price of $9.98, for a total value of $203,262.66. Following the sale, the insider now owns 1,575,419 shares of the company’s stock, valued at $15,722,681.62. The disclosure for this sale can be found here.

A hedge fund recently raised its stake in Neos Therapeutics stock. Marshall Wace LLP raised its position in Neos Therapeutics Inc. (NASDAQ:NEOS) by 11.5% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 96,162 shares of the company’s stock after buying an additional 9,929 shares during the period. Marshall Wace LLP owned 0.60% of Neos Therapeutics worth $1,377,000 at the end of the most recent quarter.

Neos Therapeutics, Inc is a pharmaceutical company. The Company is focused on developing, manufacturing and commercializing products utilizing its modified-release drug delivery technology platform. Its segment is engaged in the development, manufacturing and commercialization of pharmaceuticals. It has utilized its platform to develop its product for the treatment of attention deficit hyperactivity disorder (ADHD).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.